Trafermin

If approved, sebetralstat would be the first oral on-demand treatment for hereditary angioedema available in Japan.\n As KalVista Pharmaceuticals awaits an FDA decision on its hereditary angioedema (HAE) treatment sebetralstat, the company has sold the Japanese rights to the drug to Kaken Pharmaceutical for $11 million upfront.Alongside the upfront fee, Tokyo-based Kaken has also agreed a further $11 million payment if a regulatory milestone is hit next year. There are additional commercial milestone payments tied to the deal should sebetralstat get approved in Japan, but KalVista didn’t go into details in its April 8 release.Royalties tied to the deal would be based on the drug’s price in Japan, with a royalty rate “as a percentage of sales approximately in the mid-twenties,” KalVista explained.HAE is a genetic disease marked by low levels or dysfunction of the C1 inhibitor. Patients can be struck with bouts of severe swelling across the body, and attacks can be fatal if they impact the lungs.The FDA is expected to make a call on whether to approve sebetralstat, an oral plasma kallikrein inhibitor, in the U.S. in June as an on-demand treatment for HAE attacks in adult and pediatric patients aged 12 years and older. The application was based on a phase 3 study last year that showed patients who received either a 300-mg or 600-mg dose of sebeltralstat experienced quicker symptom relief by roughly four hours each compared to placebo.KalVista has also submitted sebetralstat to regulators in Japan. If approved, it would be the first oral on-demand treatment for HAE available in the country, the biotech noted. Kaken already markets an array of products in Japan, including hyaluronate sodium for osteoarthritis and Fiblast for skin ulcers. The company has also licensed a number of drugs from other companies, including seladelpar for primary biliary cholangitis from CymaBay Therapeutics, tildacerfont from Spruce Biosciences for congenital adrenal hyperplasia and—most recently—Alumis’ late-stage TYK2 inhibitor as a dermatology treatment“We are pleased to partner with Kaken, whose expertise and demonstrated success in the region make them well-suited to work alongside our exceptional team to bring sebetralstat to the HAE community in Japan,” KalVista CEO Ben Palleiko said in the release.“This collaboration is an important part of our strategy to expand the global reach of sebetralstat as we prepare for several commercial launches starting this year,” Palleiko added.Even if sebetralstat gets the nod from the FDA in the June, it may only have a few weeks’ headstart on donidalorsen, Ionis Pharmaceuticals’ RNA-targeted medicine for preventing HAE attacks, which is expecting a decision in August. Meanwhile, CSL secured EU approval for its prophylactic HAE drug garadacimab in February, while Intellia has a CRISPR-based gene editing candidate in development.

Tokyo-based Kaken Pharmaceutical has committed $40 million in upfront and near-term co-development payments over this year and 2026.\n Kaken Pharmaceutical will hand Alumis $40 million in the near term for the rights to develop a late-stage tyrosine kinase 2 (TYK2) inhibitor as a dermatology treatment in Japan.The drug in question, dubbed ESK-001, is Alumis’ lead candidate and is designed to correct immune dysregulation in diseases driven by proinflammatory mediators, including well-known targets like IL-23, IL-17, and type 1 interferon. Alumis has already been evaluating the twice-daily modified-release oral formulation in a pair of phase 3 trials in adults with moderate to severe plaque psoriasis.Alongside that late-stage program, Alumis is also running a phase 2b trial of ESK-001 in patients with systemic lupus erythematosus, which is expected to read out next year. The biotech said it “continues to leverage its precision data analytics platform to explore ESK-001’s potential application in other immune-mediated conditions” and is also working on a once-daily formulation.Tuesday morning\'s deal sees Tokyo-based Kaken commit $40 million in upfront and near-term codevelopment payments over this year and next, with the potential to pay up to $140 million in further milestone payments and field option payments as well as tiered royalties.In return, Kaken has the rights to ESK-001 as a dermatology drug in Japan and will be responsible for clinical and regulatory development along with commercialization in the country. There is also the option for Kaken to expand the licensing deal to cover rheumatological and gastrointestinal diseases. “We strongly believe in the potential of ESK-001 to address a range of medical needs in the dermatology space and potentially rheumatological and gastrointestinal diseases in the future,” Hiroyuki Horiuchi, president and representative director of Kaken, said in the March 25 release.Kaken markets a number of products in Japan, including hyaluronate sodium for osteoarthritis and Fiblast for skin ulcers. The company has also licensed a number of drugs from other companies, including seladelpar for primary biliary cholangitis from CymaBay Therapeutics and tildacerfont from Spruce Biosciences for congenital adrenal hyperplasia.“ESK-001 will be an important addition to the Kaken portfolio of novel therapeutics for dermatology conditions,” Horiuchi added in the release.Immune-mediated disease specialist Alumis is currently in the process of buying Acelyrin. Alumis’ pipeline is headed up by ESK-001, with the company sharing phase 2 data a year ago that showed the drug met its primary endpoint of the proportion of patients achieving a 75% improvement in the psoriasis area and severity score at Week 12 compared to placebo.“This partnership builds on the positive phase 2 clinical data of ESK-001, our next-generation oral TYK2 inhibitor, supporting our objectives to unlock its full therapeutic potential and ensure ESK-001 is widely accessible to people with immune-mediated disorders around the world,” Alumis CEO Martin Babler said in this morning’s release.